ARTICLE | Clinical News
Valeant receives complete response letter for psoriasis candidate
June 22, 2018 5:56 PM UTC
The Ortho Dermatologics unit of Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) said it received a complete response letter from FDA to an NDA for Duobrii (IDP-118) to treat plaque psoriasis.
According to Valeant, FDA had questions related to pharmacokinetic data...
BCIQ Company Profiles